The DOI matches its Crossref record; 57 of the 57 references it cites were found in a registry or an index.
Human N-methyl D-aspartate receptor antibodies alter memory and behaviour in mice
Open accessAbstract
Anti-N-methyl D-aspartate receptor (NMDAR) encephalitis is a severe neuropsychiatric disorder that associates with prominent memory and behavioural deficits. Patients' antibodies react with the N-terminal domain of the GluN1 (previously known as NR1) subunit of NMDAR causing in cultured neurons a selective and reversible internalization of cell-surface receptors. These effects and the frequent response to immunotherapy have suggested an antibody-mediated pathogenesis, but to date there is no animal model showing that patients' antibodies cause memory and behavioural deficits. To develop such a model, C57BL6/J mice underwent placement of ventricular catheters connected to osmotic pumps that delivered a continuous infusion of patients' or control cerebrospinal fluid (flow rate 0.25 µl/h, 14 days). During and after the infusion period standardized tests were applied, including tasks to assess memory (novel object recognition in open field and V-maze paradigms), anhedonic behaviours (sucrose preference test), depressive-like behaviours (tail suspension, forced swimming tests), anxiety (black and white, elevated plus maze tests), aggressiveness (resident-intruder test), and locomotor activity (horizontal and vertical). Animals sacrificed at Days 5, 13, 18, 26 and 46 were examined for brain-bound antibodies and the antibody effects on total and synaptic NMDAR clusters and protein concentration using confocal microscopy and immunoblot analysis. These experiments showed that animals infused with patients' cerebrospinal fluid, but not control cerebrospinal fluid, developed progressive memory deficits, and anhedonic and depressive-like behaviours, without affecting other behavioural or locomotor tasks. Memory deficits gradually worsened until Day 18 (4 days after the infusion stopped) and all symptoms resolved over the next week. Accompanying brain tissue studies showed progressive increase of brain-bound human antibodies, predominantly in the hippocampus (maximal on Days 13-18), that after acid extraction and characterization with GluN1-expressing human embryonic kidney cells were confirmed to be against the NMDAR. Confocal microscopy and immunoblot analysis of the hippocampus showed progressive decrease of the density of total and synaptic NMDAR clusters and total NMDAR protein concentration (maximal on Day 18), without affecting the post-synaptic density protein 95 (PSD95) and α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors. These effects occurred in parallel with memory and other behavioural deficits and gradually improved after Day 18, with reversibility of symptoms accompanied by a decrease of brain-bound antibodies and restoration of NMDAR levels. Overall, these findings establish a link between memory and behavioural deficits and antibody-mediated reduction of NMDAR, provide the biological basis by which removal of antibodies and antibody-producing cells improve neurological function, and offer a model for testing experimental therapies in this and similar disorders.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The tail suspension test: A new method for screening antidepressants in mice
Steru, L., Chermat, R., Thierry, B., & Simon, P. (1985) · Psychopharmacology · doi:10.1007/bf00428203 · Cited by 3,534
Anti-NMDA-receptor encephalitis: case series and analysis of the effects of antibodies
Dalmau, J., Gleichman, A. J., Hughes, E. G., Rossi, J. E., Peng, X., Lai, M., Dessain, S. K., Rosenfeld, M. R., Balice-Gordon, R., & Lynch, D. R. (2008) · The Lancet Neurology · doi:10.1016/s1474-4422(08)70224-2 · Cited by 3,488
Self-citationBehavioral despair in mice: a primary screening test for antidepressants.
Porsolt, R. D., Bertin, A., & Jalfre, M. (1977) · PubMed · Cited by 3,320
Titulaer, M. J., McCracken, L., Gabilondo, I., Armangué, T., Glaser, C., Iizuka, T., Honig, L. S., Benseler, S. M., Kawachi, I., Martinez-Hernandez, E., et al. (2013) · The Lancet Neurology · doi:10.1016/s1474-4422(12)70310-1 · Cited by 3,165 · cited 3×
“80% of the patients have substantial recovery after immunotherapy (accompanied by removal of an underlying tumour, usually an ovarian teratoma, when appropriate), or sometimes spontaneously (Iizuka et al., 2008; Titulaer et al., 2013).”
Self-citationRecent advances in the phencyclidine model of schizophrenia
(1991) · American Journal of Psychiatry · doi:10.1176/ajp.148.10.1301 · Cited by 2,904
Paraneoplastic anti– N ‐methyl‐ D ‐aspartate receptor encephalitis associated with ovarian teratoma
Dalmau, J., Tüzün, E., Wu, H., Masjuan, J., Rossi, J. E., Voloschin, A., Baehring, J. M., Shimazaki, H., Koide, R., King, D., et al. (2007) · Annals of Neurology · doi:10.1002/ana.21050 · Cited by 2,492
Glutamate receptor dysfunction and schizophrenia
Olney, J. W. (1995) · Archives of General Psychiatry · doi:10.1001/archpsyc.1995.03950240016004 · Cited by 1,685 · cited 1×
“…the similarities between the human disease and the phenotypes induced by NMDAR antagonists (phencyclidine , ketamine or MK801) have suggested points of convergence with one of the most influential theories of schizophrenia, the NMDA-hypofunction model (Olney and Farber, 1995; Kehrer et al., 2008).”
Regulation of NMDA receptor trafficking by amyloid-β
Snyder, E. M., Nong, Y., Almeida, C. G., Paul, S., Moran, T., Choi, E. Y., Nairn, A. C., Salter, M. W., Lombroso, P. J., Gouras, G. K., et al. (2005) · Nature Neuroscience · doi:10.1038/nn1503 · Cited by 1,561 · cited 1×
“…NMDAR that cause psychosis) (Weiner et al., 2000; Gunduz-Bruce, 2009), and brain tissue studies of patients with schizophrenia or Alzheimer's disease in which several molecular pathways that modulate glutamate receptor trafficking or function are affected (Snyder et al., 2005; Hahn et al., 2006).”
Preliminary report of a simple animal behavior model for the anxiolytic effects of benzodiazepines
Crawley, J., & Goodwin, F. K. (1980) · Pharmacology Biochemistry and Behavior · doi:10.1016/0091-3057(80)90067-2 · Cited by 1,425
Jentsch, J. (1999) · Neuropsychopharmacology · doi:10.1016/s0893-133x(98)00060-8 · Cited by 1,314
Cited by
A clinical approach to diagnosis of autoimmune encephalitis
Graus, F., Titulaer, M. J., Balu, R., Benseler, S., Bien, C. G., Cellucci, T., Cortese, I., Dale, R. C., Gelfand, J. M., Geschwind, M., et al. (2016) · The Lancet Neurology · doi:10.1016/s1474-4422(15)00401-9 · Cited by 4,516
Self-citationAntibody-Mediated Encephalitis
Dalmau, J., & Graus, F. (2018) · New England Journal of Medicine · doi:10.1056/nejmra1708712 · Cited by 1,329
Self-citationDalmau, J., Armangué, T., Planagumà, J., Radosevic, M., Mannara, F., Leypoldt, F., Geis, C., Lancaster, E., Titulaer, M. J., Rosenfeld, M. R., et al. (2019) · The Lancet Neurology · doi:10.1016/s1474-4422(19)30244-3 · Cited by 899
Self-citationStructure, Function, and Pharmacology of Glutamate Receptor Ion Channels
Hansen, K. B., Wollmuth, L. P., Bowie, D., Furukawa, H., Menniti, F. S., Sobolevsky, A. I., Swanson, G. T., Swanger, S. A., Greger, I. H., Nakagawa, T., et al. (2021) · Pharmacological Reviews · doi:10.1124/pharmrev.120.000131 · Cited by 686
Dalmau, J., Geis, C., & Graus, F. (2017) · Physiological Reviews · doi:10.1152/physrev.00010.2016 · Cited by 628
Self-citationMechanisms of Autoantibody-Induced Pathology
Ludwig, R. J., Vanhoorelbeke, K., Leypoldt, F., Kaya, Z., Bieber, K., McLachlan, S. M., Komorowski, L., Luo, J., Cabral-Marques, O., Hammers, C. M., et al. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.00603 · Cited by 469
Self-citationThe hippocampus in aging and disease: From plasticity to vulnerability
Bartsch, T., & Wulff, P. (2015) · Neuroscience · doi:10.1016/j.neuroscience.2015.07.084 · Cited by 465
The Diagnosis and Treatment of Autoimmune Encephalitis
Lancaster, E. (2016) · Journal of Clinical Neurology · doi:10.3988/jcn.2016.12.1.1 · Cited by 437
B cells in autoimmune and neurodegenerative central nervous system diseases
Sabatino, J. J., Pröbstel, A.-K., & Zamvil, S. S. (2019) · Nature Reviews Neuroscience · doi:10.1038/s41583-019-0233-2 · Cited by 343
Autoantibodies in neurological disease
Prüss, H. (2021) · Nature Reviews Immunology · doi:10.1038/s41577-021-00543-w · Cited by 319
Kreye, J., Wenke, N. K., Chayka, M., Leubner, J., Murugan, R., Maier, N., Jurek, B., Ly, L.-T., Brandl, D., Rost, B. R., et al. (2016) · Brain · doi:10.1093/brain/aww208 · Cited by 290
Williams, T. J., Benavides, D. R., Patrice, K.-A., Dalmau, J. O., de Ávila, A. L. R., Le, D. T., Lipson, E. J., Probasco, J. C., & Mowry, E. M. (2016) · JAMA Neurology · doi:10.1001/jamaneurol.2016.1399 · Cited by 276
Self-citationAutoimmune post–herpes simplex encephalitis of adults and teenagers
Armangue, T., Moris, G., Cantarín-Extremera, V., Conde, C. E., Rostasy, K., Erro, M. E., Portilla-Cuenca, J. C., Turón-Viñas, E., Málaga, I., Muñoz-Cabello, B., et al. (2015) · Neurology · doi:10.1212/wnl.0000000000002125 · Cited by 273
Self-citationImaging of autoimmune encephalitis – Relevance for clinical practice and hippocampal function
Heine, J., Prüss, H., Bartsch, T., Ploner, C. J., Paul, F., & Finke, C. (2015) · Neuroscience · doi:10.1016/j.neuroscience.2015.05.037 · Cited by 272
Treatment strategies for autoimmune encephalitis
Shin, Y.-W., Lee, S.-T., Park, K.-I., Jung, K.-H., Jung, K.-Y., Lee, S. K., & Chu, K. (2018) · Therapeutic Advances in Neurological Disorders · doi:10.1177/1756285617722347 · Cited by 266
Infectious immunity in the central nervous system and brain function
Klein, R. S., Garber, C., & Howard, N. (2017) · Nature Immunology · doi:10.1038/ni.3656 · Cited by 235
Linking glutamate receptor movements and synapse function
Groc, L., & Choquet, D. (2020) · Science · doi:10.1126/science.aay4631 · Cited by 207
Coles, J. A., Myburgh, E., Brewer, J. M., & McMenamin, P. G. (2017) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2017.05.002 · Cited by 123
Platt, M. P., Agalliu, D., & Cutforth, T. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.00442 · Cited by 108
Castillo‐Gomez, E., Kästner, A., Steiner, J., Schneider, A., Hettling, B., Poggi, G., Ostehr, K., Uhr, M., Asif, A. R., Matzke, M., et al. (2016) · Annals of Neurology · doi:10.1002/ana.24545 · Cited by 89
Wesselingh, R., Butzkueven, H., Buzzard, K., Tarlinton, D., O'Brien, T. J., & Monif, M. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.02066 · Cited by 83
Metadata
- Authors
- Planagumà, J., Leypoldt, F., Mannara, F., Gutiérrez-Cuesta, J., Martín-García, E., Aguilar, E., Titulaer, M. J., Petit-Pedrol, M., Jain, A., Balice-Gordon, R., Lakadamyali, M., Graus, F., Maldonado, R., & Dalmau, J.
- Venue
- Brain
- Publisher
- Oxford University Press (OUP)
- Published
- 2014-11-11
- Volume
- 138
- Issue
- 1
- Pages
- 94-109
- ISSN
- 0006-8950 (ISSN-L)
- 1460-2156
- OpenAlex
- W2075313898
- Cited by
- 489
- References
- 57
- FWCI
- 23.48
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.